Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology : A Population-Based Study. / Bojesen, Rasmus Dahlin; Riis, Lene Buhl; Høgdall, Estrid; Nielsen, Ole Haagen; Jess, Tine.

In: Clinical Gastroenterology and Hepatology, Vol. 15, No. 12, 12.2017, p. 1900-1907.e2.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bojesen, RD, Riis, LB, Høgdall, E, Nielsen, OH & Jess, T 2017, 'Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study', Clinical Gastroenterology and Hepatology, vol. 15, no. 12, pp. 1900-1907.e2. https://doi.org/10.1016/j.cgh.2017.06.051

APA

Bojesen, R. D., Riis, L. B., Høgdall, E., Nielsen, O. H., & Jess, T. (2017). Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. Clinical Gastroenterology and Hepatology, 15(12), 1900-1907.e2. https://doi.org/10.1016/j.cgh.2017.06.051

Vancouver

Bojesen RD, Riis LB, Høgdall E, Nielsen OH, Jess T. Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. Clinical Gastroenterology and Hepatology. 2017 Dec;15(12):1900-1907.e2. https://doi.org/10.1016/j.cgh.2017.06.051

Author

Bojesen, Rasmus Dahlin ; Riis, Lene Buhl ; Høgdall, Estrid ; Nielsen, Ole Haagen ; Jess, Tine. / Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology : A Population-Based Study. In: Clinical Gastroenterology and Hepatology. 2017 ; Vol. 15, No. 12. pp. 1900-1907.e2.

Bibtex

@article{1db465f475804cf68ebe1960f55540ec,
title = "Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study",
abstract = "BACKGROUND & AIMS: Inflammatory bowel disease (IBD) may increase risk of small bowel cancer (SBC). However, little is known of the characteristics and features of IBD-SBC, due to a low number of cases worldwide. We performed a population-based study of IBD and SBC to calculate risk and increase our understanding of clinical characteristics and histopathological and molecular features.METHODS: The study population consisted of all individuals aged 16 years or older living in Denmark during 1978-2010. Through linkage between national registers and subsequent scrutiny of medical records and pathology descriptions, we identified 40 cases of IBD-SBC. Risk was calculated by standardized incidence ratio (SIR) (observed/expected); patient characteristics were derived from medical files, and surgery specimens were obtained from hospitals nationwide for histopathological and molecular analyses.RESULTS: During 241,620 person-years of follow-up, 23 patients with Crohn's disease developed small bowel adenocarcinoma (SIR, 14.38; 95% confidence interval, 8.78-22.20) and 9 developed neuroendocrine tumors (SIR, 6.83; 95% confidence interval, 3.13-12.97). No significantly increased risk of SBC was found among patients with ulcerative colitis. Most patients with SBC had moderate-to-severe Crohn's disease with small bowel and upper gastrointestinal involvement. Assessment of surgical specimens of small bowel adenocarcinomas revealed a clear transition from inflammation to dysplasia and cancer, whereas no tumors had evidence of microsatellite instability.CONCLUSIONS: In a population-based study of patients in Denmark with IBD and SBC, we found risk of adenocarcinomas and neuroendocrine tumors to be increased among persons with Crohn's disease. Most patients with IBD-SBC had extensive IBD of moderate-to-severe activity. Adenocarcinomas appeared to develop via an inflammation-dysplasia-carcinoma pathway, but differed from IBD-related colorectal adenocarcinomas in their molecular features.",
author = "Bojesen, {Rasmus Dahlin} and Riis, {Lene Buhl} and Estrid H{\o}gdall and Nielsen, {Ole Haagen} and Tine Jess",
note = "Copyright {\textcopyright} 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = dec,
doi = "10.1016/j.cgh.2017.06.051",
language = "English",
volume = "15",
pages = "1900--1907.e2",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B.Saunders Co.",
number = "12",

}

RIS

TY - JOUR

T1 - Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology

T2 - A Population-Based Study

AU - Bojesen, Rasmus Dahlin

AU - Riis, Lene Buhl

AU - Høgdall, Estrid

AU - Nielsen, Ole Haagen

AU - Jess, Tine

N1 - Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2017/12

Y1 - 2017/12

N2 - BACKGROUND & AIMS: Inflammatory bowel disease (IBD) may increase risk of small bowel cancer (SBC). However, little is known of the characteristics and features of IBD-SBC, due to a low number of cases worldwide. We performed a population-based study of IBD and SBC to calculate risk and increase our understanding of clinical characteristics and histopathological and molecular features.METHODS: The study population consisted of all individuals aged 16 years or older living in Denmark during 1978-2010. Through linkage between national registers and subsequent scrutiny of medical records and pathology descriptions, we identified 40 cases of IBD-SBC. Risk was calculated by standardized incidence ratio (SIR) (observed/expected); patient characteristics were derived from medical files, and surgery specimens were obtained from hospitals nationwide for histopathological and molecular analyses.RESULTS: During 241,620 person-years of follow-up, 23 patients with Crohn's disease developed small bowel adenocarcinoma (SIR, 14.38; 95% confidence interval, 8.78-22.20) and 9 developed neuroendocrine tumors (SIR, 6.83; 95% confidence interval, 3.13-12.97). No significantly increased risk of SBC was found among patients with ulcerative colitis. Most patients with SBC had moderate-to-severe Crohn's disease with small bowel and upper gastrointestinal involvement. Assessment of surgical specimens of small bowel adenocarcinomas revealed a clear transition from inflammation to dysplasia and cancer, whereas no tumors had evidence of microsatellite instability.CONCLUSIONS: In a population-based study of patients in Denmark with IBD and SBC, we found risk of adenocarcinomas and neuroendocrine tumors to be increased among persons with Crohn's disease. Most patients with IBD-SBC had extensive IBD of moderate-to-severe activity. Adenocarcinomas appeared to develop via an inflammation-dysplasia-carcinoma pathway, but differed from IBD-related colorectal adenocarcinomas in their molecular features.

AB - BACKGROUND & AIMS: Inflammatory bowel disease (IBD) may increase risk of small bowel cancer (SBC). However, little is known of the characteristics and features of IBD-SBC, due to a low number of cases worldwide. We performed a population-based study of IBD and SBC to calculate risk and increase our understanding of clinical characteristics and histopathological and molecular features.METHODS: The study population consisted of all individuals aged 16 years or older living in Denmark during 1978-2010. Through linkage between national registers and subsequent scrutiny of medical records and pathology descriptions, we identified 40 cases of IBD-SBC. Risk was calculated by standardized incidence ratio (SIR) (observed/expected); patient characteristics were derived from medical files, and surgery specimens were obtained from hospitals nationwide for histopathological and molecular analyses.RESULTS: During 241,620 person-years of follow-up, 23 patients with Crohn's disease developed small bowel adenocarcinoma (SIR, 14.38; 95% confidence interval, 8.78-22.20) and 9 developed neuroendocrine tumors (SIR, 6.83; 95% confidence interval, 3.13-12.97). No significantly increased risk of SBC was found among patients with ulcerative colitis. Most patients with SBC had moderate-to-severe Crohn's disease with small bowel and upper gastrointestinal involvement. Assessment of surgical specimens of small bowel adenocarcinomas revealed a clear transition from inflammation to dysplasia and cancer, whereas no tumors had evidence of microsatellite instability.CONCLUSIONS: In a population-based study of patients in Denmark with IBD and SBC, we found risk of adenocarcinomas and neuroendocrine tumors to be increased among persons with Crohn's disease. Most patients with IBD-SBC had extensive IBD of moderate-to-severe activity. Adenocarcinomas appeared to develop via an inflammation-dysplasia-carcinoma pathway, but differed from IBD-related colorectal adenocarcinomas in their molecular features.

U2 - 10.1016/j.cgh.2017.06.051

DO - 10.1016/j.cgh.2017.06.051

M3 - Journal article

C2 - 28694132

VL - 15

SP - 1900-1907.e2

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 12

ER -

ID: 195153457